These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 39039285

  • 1. Home blood pressure-lowering effect of a non-steroidal mineralocorticoid receptor blocker, esaxerenone, versus trichlormethiazide for uncontrolled hypertension: the EXCITE-HT randomized controlled study.
    Kario K, Ohbayashi H, Hashimoto M, Itabashi N, Kato M, Uchiyama K, Hirano K, Nakamura N, Miyamoto T, Nagashima H, Kajiyama S, Ishida H, Imai E, Ebe Y, Ohishi M, Katsuya T, Taguchi T, Tanabe A, Shimosawa T, EXCITE-HT investigators.
    Hypertens Res; 2024 Sep; 47(9):2435-2446. PubMed ID: 39039285
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Exploratory study on the relationship between urinary sodium/potassium ratio, salt intake, and the antihypertensive effect of esaxerenone: the ENaK Study.
    Katsuya T, Inobe Y, Uchiyama K, Nishikawa T, Hirano K, Kato M, Fukui T, Hatta T, Iwasaki A, Ishii H, Sugiura T, Taguchi T, Tanabe A, Sugimoto K, Shimosawa T, ENaK investigators.
    Hypertens Res; 2024 Apr; 47(4):835-848. PubMed ID: 38212366
    [Abstract] [Full Text] [Related]

  • 5. Nighttime home blood pressure lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension: the EARLY-NH study.
    Kario K, Nishizawa M, Kato M, Ishii H, Uchiyama K, Nagai M, Takahashi N, Asakura T, Shiraiwa T, Yoshida T, Kaneshiro M, Taguchi T, Shiosakai K, Sugimoto K.
    Hypertens Res; 2023 Jul; 46(7):1782-1794. PubMed ID: 37173430
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study.
    Ito S, Itoh H, Rakugi H, Okuda Y, Yamakawa S.
    J Hum Hypertens; 2019 Jul; 33(7):542-551. PubMed ID: 31113987
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension.
    Rakugi H, Ito S, Itoh H, Okuda Y, Yamakawa S.
    Hypertens Res; 2019 Dec; 42(12):1932-1941. PubMed ID: 31554937
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Left Ventricular Hypertrophy (ESES-LVH) Study: A Multicenter, Open-Label, Prospective, Interventional Study.
    Yamamoto E, Usuku H, Sueta D, Suzuki S, Nakamura T, Matsui K, Matsushita K, Iwasaki T, Sakaino N, Sakanashi T, Hirayama K, Kurokawa H, Kikuta K, Yamamoto N, Sato K, Tokitsu T, Taguchi T, Shiosakai K, Sugimoto K, Tsujita K, ESES-LVH investigators.
    Adv Ther; 2024 Mar; 41(3):1284-1303. PubMed ID: 38310194
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study.
    Kario K, Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S.
    Am J Hypertens; 2021 May 22; 34(5):540-551. PubMed ID: 33165570
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antihypertensive Effect of Long-Term Monotherapy with Esaxerenone in Patients with Essential Hypertension: Relationship Between Baseline Urinary Sodium Excretion and Its Antihypertensive Effect.
    Ichikawa S, Tsutsumi J, Sugimoto K, Yamakawa S.
    Adv Ther; 2022 Oct 22; 39(10):4779-4791. PubMed ID: 35976603
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of esaxerenone (CS-3150) in primary hypertension: a meta-analysis.
    Sun R, Li Y, Lv L, Zhang W, Guo X.
    J Hum Hypertens; 2024 Feb 22; 38(2):102-109. PubMed ID: 38177694
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.